AIMT

SC 13G/A - Aimmune Therapeutics, Inc. (0001631650) (Subject)

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT) who held Aimmune securities as of the close of the tender offer on October 9, 2020 (the "Class Period"), and have been harmed by Aimmune and its board of directors' (the "Board") alleged violations of Sections 14(e) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to Société des Produits Nestlé S.A.

Vevey, October 14, 2020 Nestlé completes acquisition of Aimmune Therapeutics Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc's global pharmaceutical business. "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-bassed nutritional solutions to support healthier lives,” said Greg Behar, CEO of NHSc. "Aimmune's PALFORZIA®, the first medication approved for treating peanut allergy, is a game-ch

VEVEY, Switzerland, Oct. 13, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. ("Purchaser"), to purchase all of the outstanding shares ("Shares") of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) ("Aimmune"), other than any Shares held by Nestlé and its affiliates, for a price of USD 34.50 per Share (the "Offer Price"), net to the seller thereof in cash, without interest and subject to any withholding taxes (the "Offer"), which was made upon the terms and subject to the conditions set forth in the Offer to Purchase (the "Offer to Purchase") and related Letter of T

Vevey, October 13, 2020 Nestlé announces results of tender offer for Aimmune Therapeutics, Inc. Société des Produits Nestlé S.A. ("Nestlé") today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. ("Purchaser"), to purchase all of the outstanding shares ("Shares") of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) ("Aimmune"), other than any Shares held by Nestlé and its affiliates, for a price of USD 34.50 per Share (the "Offer Price"), net to the seller thereof in cash, without interest and subject to any withholding taxes (the "Offer"), which was made upon the terms and subject to the conditions set forth in the Offer to Purchase (

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Innovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest substantial amounts of time, effort, and resources in key areas of research and innovation are critical in the advancement treatment options across the board. On the front lines of research and development in the area of inflammation, which typically occurs in the body as a natural response to threats such as infection or injury can cause severe damage and even death, is 180 Life Sciences Corp. (NASDAQ: KBLM) (180 Profile). The company is focused on groundbreaking studies in clinical programs designed to develo

NEW YORK, Sept. 17, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Varian Medical Systems, Inc. (NYSE: VAR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Siemens Healthineers AG for $177.50 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/varian-medical-systems-inc-var-stock-merger-siemens. Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AIMT to Sociétés des Produits Nestlé, S.A. for $34.50 per share. If you are a AIMT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Akcea Therapeutics, Inc. (NASDAQ:AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AKCA to

VEVEY, Switzerland, Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) ("Aimmune") today for a price of USD 34.50 per share, net to the seller in cash, without interest and subject to any withholding taxes (the "Offer").  The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase (the "Offer to Purchase"), and related Letter of Transmittal and other related materials that will be filed by Nestlé and Pu

Vevey, September 14, 2020 Nestlé commences tender offer for Aimmune Therapeutics, Inc. Société des Produits Nestlé S.A. (“Nestlé”) announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. (“Purchaser”), is commencing today a cash tender offer to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) (“Aimmune”) today for a price of USD 34.50 per share, net to the seller in cash, without interest and subject to any withholding taxes (the “Offer”). The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase (the “Offer to Purchase”), and related Letter of Transmittal and other related material

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Cambium Learning Group for $30 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/rosetta-stone-inc-rst-stock-merger-cambium/. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entitie